ANZCTR search results

This will be a double-blind, multicenter, parallel arms study of low and high dose levels of BRP-180 evaluated for improving wakefulness and reducing cataplexy in patients with Type 1 Narcolepsy. This trial will consist of 3 study periods: 1. Screening and Observation Period: Day -42 to Day 0. Sleepiness and cataplexy diary recording daily. 2. Treatment Period: Weeks 1-8. Parallel arms treatment period. During the treatment period, patients self-administer the allocated treatment (low doses of BRP-180, high doses of BRP-180, or placebo) once a day for 8 consecutive weeks.Sleepiness and cataplexy diary recording. 3. Follow-up Period: Week 9-12. Continued sleepiness and cataplexy diary recording daily and bi-weekly telehealth check-ins

It is hypothesised that there will be a correlation between the overall exposure to vancomycin of the whole blood (as represented by drawn serum samples) and subdermal tissue (as represented by ISF concentrations measured by the Nutromics device). This study is to assess the validity of this hypothesis in healthy human subjects, as a precursor to studies in the Device’s intended use population. It is designed to be able to deconvolute within participant effects from between participant effects, by giving multiple different doses to the same participants and repeating over multiple participants.

Online symptom checkers are digital health tools allowing health consumers to input symptoms to receive triage or diagnosis advice. If appropriate, another important feature is to provide consumers with self-care advice for managing their symptoms at home. Integrating Generative Artificial Intelligence (AI) into symptom checkers may help address unmet needs of diverse users, including those with lower health literacy. A retrieval-augmented generation (RAG) framework may be particularly useful by addressing concerns around accuracy via greater control of the quality of information informing the AI output. However, it is unknown how to best communicate the use of RAG generative AI in symptom checkers, nor how to present the advice. This project aims to 1) evaluate the effects of different presentations of generative AI symptom checker self-care advice on intentions, trustworthiness and understanding of the advice, and 2) explore in-depth user responses and perspectives on AI generated triage and self-care advice in an online symptom checker.

This will be a Phase 1, single center, comparative bioavailability, open-label, randomized, single-dose, 2-period, crossover study to evaluate the relative bioavailability of 2 formulations of GT-02287 in healthy adult participants. Participants will receive a single oral dose (10 mg/kg of GT-02287) of each formulation, in fasting conditions, in a crossover fashion during 2 periods.

The primary aim of this project is to evaluate the effectiveness of accessible cervical screening information for people supporting people with intellectual disability to make an informed decision about whether to have a cervical screening test. Who is it for? You may be eligible for this study if you area family member or support person (unpaid or paid, for example, disability support worker or family carer) of a person/people with intellectual disability who are eligible for screening in the National Cervical Screening Program. Study details: Participants will receive a link to a website with accessible cervical screening information, including Easy Read information and videos about the Cervical Screening Test, and resources to support communication about the test with people with intellectual disability and healthcare providers. They will have access to these resources for four months. Participants will be asked to complete a short survey before and after accessing these resources. It is hoped that the findings of this study will help us to improve access to and experiences of cervical screening amongst people with intellectual disability.

The primary aim of this project is to evaluate the effectiveness of online training for healthcare providers to support their cervical screening practice for people with intellectual disability. Who is it for? You may be eligible for this study if you are a GP or nurse working in Australia. Study details: Participants will have access an online training module designed to help them provide better cervical screening for people with intellectual disabilities. The training covers topics such as the importance of cervical screening, communication strategies, and managing consent. They will have access to this training for four months. Participants will be asked to complete a short survey before and after accessing the training. It is hoped that the findings of this study will help us to improve access to and experiences of cervical screening amongst people with intellectual disability.

The goal of this study is to determine whether topical metronidazole ointment works to improve healing rates and achieve complete healing without causing discomfort or side effects for non-healing pilonidal wounds. Based on a previous pilot study, we hypothesize that 10% topical metronidazole will be better than placebo in achieving these outcomes

The primary purpose of this study is to evaluate the effectiveness of the WDEP.AI digital platform in enhancing healthcare professionals’ knowledge and skills in diabetes management. This platform provides structured and systematic learning to address knowledge gaps, aiming to reduce errors in care and improve patient outcomes. We hypothesise that healthcare professionals who use the WDEP.AI platform will demonstrate improved competencies, leading to safer and more effective diabetes care.

This research is essential as it will to overcome the documented discrepancies in patient understanding and provide a video reference tool for patients to facilitate better engagement in decision making. The research is expected to benefit patients undergoing incisional glaucoma surgery and ophthalmologists, allowing them to improve their consultations and provide more effective and efficient patient-centred care.

Worsening kidney function is common after cardiac surgery. During cardiac surgery, cardiopulmonary bypass (CPB) is commonly utilised to deliver blood around the body However, the use of CPB is known to decrease blood flow to the kidneys compared to normal, putting the kidneys at risk of harm. Increasing overall CPB blood flow to the whole body has minimised kidney harm in small studies. However, the benefit of routinely increased CPB blood flow has not been tested in real-world settings. In order to work towards a large trial that applies high CPB blood flow routinely, we aim to demonstrate the feasibility of targeting different CPB blood flow targets in two different hospitals. Adult non-female patients having cardiac surgery who: require normal temperatures to manage their surgery; have normal oxygen-carrying capacity and without severe kidney disease will randomly receive blood flows at the highest range of acceptable CPB flow or blood flows at the middle of that range. Afterwards, routinely collected data related to kidney outcomes and other outcomes will be collected. An extra blood test will be collected comparing red cell breakdown in both groups. This trial is expected to demonstrate feasibility for a larger trial.